



ESUR16

23rd Meeting of the EAU Section of
Urological Research

20-22 October 2016, Parma, Italy

www.esur16.org

esur

EAU
European
Association
of Urology

Scientific Programme

Thursday, 20 October 2016

- 13.00 – 14.30** **Registration**
- 14.30 – 14.40** **Opening**
Kerstin Junker, Homburg (DE) ESUR Chair
Saverio Bettuzzi, Parma (IT) Meeting Chair
- 14.40 – 15.55** **Session 1**
Immunotherapy for advanced cancer: Checkpoint inhibitors
Chairs: Saverio Bettuzzi, Parma (IT)
 Egbert Oosterwijk, Nijmegen (NL)
- 14.40 – 15.05** **Introduction**
Elfriede Nossner, Munich (DE)
- 15.05 – 15.30** **ESOU lecture: Clinical trials using checkpoint inhibitors in urological carcinomas**
George Thalmann, Berne (CH)
- 15.30 – 15.55** **Potential biomarkers for immune therapy**
Nicholas McGranahan, London (GB)
- 15.55 – 16.20** **Break**
- 16.20 – 18.00** **Session 2**
Subtyping in bladder cancer
Chairs: Yves Allory, Creteil (FR)
 Margaret Knowles, Leeds (GB)
- 16.20 – 16.45** **What can we really learn from breast cancer?**
Francois Radvanyi, Paris (FR)
- 16.45 – 17.10** **Individualised therapy in bladder cancer: Do we know the right targets?**
Jonathan Rosenberg, New York (US)
- 17.10 – 18.00** **Short presentations 1**
- 17.10 – 17.20 O-1 ***MiR-520f reverses EMT and sensitizes tumor cells to chemotherapy***
Jasmijn Van Kampen, Nijmegen (NL)
- 17.20 – 17.30 O-2 ***Differentially expressed long noncoding RNAs in bladder cancer***
Edyta Borkowska, Lodz (PL)
- 17.30 – 17.40 O-3 ***Molecular spectrum of heterogeneity in basal-like subtype of bladder cancer***
Nanour Sirab, Creteil (FR)
- 17.40 – 17.50 O-4 ***Evaluation of analytical and diagnostic performance of urinary ELISA and MRM (Multiple Reaction Monitoring) assays for bladder cancer monitoring***
Jeronymos Zoidakis, Athens (GR)
- 17.50 – 18.00 O-5 ***Noninvasive bladder cancer diagnosis using a DNA methylation biomarker panel***
Lourdes Mengual, Barcelona (ES)

Friday 21 October 2016

- 08.45 – 11.00** **Session 3**
Tumour heterogeneity
Chairs: Anders Bjartell, Malmo (SE)
 Kerstin Junker, Homburg (DE)
- 08.45 – 09.15** **Tumour heterogeneity in kidney cancer: Molecular genetic picture**
Samra Turajlic, London (GB)
- 09.15 – 09.45** **Tumour heterogeneity in kidney cancer: Important for clinical decision?**
Alessandro Volpe, Novara (IT)
- 09.45 – 10.15** **Diagnostic challenges of clonal heterogeneity in prostate cancer**
Michael Haffner, Baltimore (US)
- 10.15 – 10.30** **The evolutionary history of lethal metastatic cancer**
Colin Cooper, Sutton (GB)
- 10.30 – 11.00** **Tumour heterogeneity in prostate cancer: Implications for therapy**
Michael Stöckle, Homburg (DE)
- 11.00 – 11.30** **Break**
- 11.30 -13.00** **Session 4**
Chairs: Jocelyn Ceraline, Strasbourg (FR)
 Guido Jenster, Rotterdam (NL)
- 11.30 – 12.00** **Molecular characterisation of disseminated cancer cells in prostate cancer: An insight into mechanisms of metastasis**
Miodrag Guzvic, Regensburg (DE)
- 12.00 – 13.00** **Short presentations 2**
- 12.00 – 12.10** **O-6 *The kinetics of urinary and blood derived cell free mutant DNA in muscle invasive bladder cancer***
Keval Patel, Cambridge (GB)
- 12.10 – 12.20** **O-7 *Development and validation of a prediction model using plasma proteins for second-line therapy response in metastatic renal cell carcinoma***
Sebastian Hölter, Homburg (DE)
- 12.20 – 12.30** **O-8 *Potential role of a novel urinary biomarker-based risk score to select patients for multiparametric MRI for prostate cancer detection***
Jack Schalken, Nijmegen (NL)
- 12.30 – 12.40** **O-9 *EVQuant: A novel extracellular vesicle quantification and characterization assay for scientific and diagnostic use***
Thomas Hartjes, Rotterdam (NL)
- 12.40 – 12.50** **O10 *Androgen receptor variants and microenvironment in prostate cancer***
Edwige Schreyer, Strasbourg (FR)
- 12.50 – 13.00** **O11 *Metastatic risk for ccRCC patients can be predicted by alterations in specific chromosomal regions***
Julia Grimm, Homburg (DE)
- 13.00 – 14.00** **Lunch**
- 14.00 – 15.00** **Poster session 1**
Poster numbers P1 – P28

15.00 – 17.30

Session 5

Tumour metabolism and transformation

Chairs: Zoran Culig, Innsbruck (AT)

Antonia Vlahou, Athens (GR)

15.00 – 15.30

Hallmarks of metabolic reprogramming in cancer

Ferdinando Chiaradonna, Milan (IT)

15.30 – 16.00

RCC a metabolic disease: Consequences for diagnosis and prognosis

Matthias Schwab, Stuttgart (DE)

16.00 – 16.30

The polyamines metabolism and prostate cancer

Federica Rizzi, Parma (IT)

16.30 – 17.30

Short presentations 3

16.30 – 16.40

O12 *Diminished response of prostate cancer cells to antiandrogens upon co-culture with cancer-associated fibroblasts as shown in a 3-dimensional prostate cancer epithelial-stromal organoid model*

Iris Eder, Innsbruck (AT)

16.40 – 16.50

O13 *ESE3/EHF controls the Lin28/let-7 microRNA axis to restrain cell transformation and cancer stem-like compartment in prostate cancer*

Domenico Albino, Bellinzona (CH)

16.50 – 17.00

O14 *Transcriptional downregulation of cholesterol synthesis revealed as a hallmark for prostate cancer after adjustment for confounding stroma*

Morten Rye, Trondheim (NO)

17.00 – 17.10

O15 *The Cripto/GRP78 signalling axis in the cross-talk of metastatic prostate cancer cells with the bone microenvironment*

Federico La Manna, Leiden (NL)

17.10 – 17.20

O16 *Interleukin-4 in the prostate cancer microenvironment increases clonogenic potential of tumour initiating cells*

Giovanna Nappo, York (GB)

17.20 – 17.30

O17 *Delineation of advanced prostate cancer evolution identifies chromothripsis as a polyclonal event selecting for FKPB4/52 as a driver of castration resistance*

David Müller, Basel (CH)

Saturday 22 October 2016

- 09.00- 11.00** **Session 6**
Viruses and tumour diseases
Chairs: Mariangela Mancini, Padova (IT)
 Gabri Van Der Pluijm, Leiden (NL)
- 09.00 – 09.25** **Introduction to virus-induced carcinogenesis**
Sigrun Smola, Homburg (DE)
- 09.25 – 09.55** **HPV: Role for penile cancer tumour biology and therapy**
Rosa Djajadiningrat, Amsterdam (NL)
- 09.55 – 10.20** **Virus based tumour therapy**
Jean Rommelaere, Heidelberg (DE)
- 10.20 – 11.00** **Short presentations 4**
- 10.20 – 10.30** **O18 *Human Papillomavirus (HPV) infection in penile squamous cell carcinomas (SCC): correlation with histopathology and prognosis***
Sebastian Hölters, Homburg (DE)
- 10.30 – 10.40** **O19 *Tumour escape in the microenvironment of penile carcinoma***
Sarah Ottenhof, Amsterdam (NL)
- 10.40 – 10.50** **O20 *P53-dependent miR-205 promotor activation by Metformin (MF) in prostate cancer cells – impact on epithelial to mesenchymal transition (EMT)***
Charis Kalogirou, Würzburg (DE)
- 10.50 – 11.00** **O21 *The bi-directional interaction of AR and IL6 signalling in the response to enzalutamide in prostate cancer cells***
Florian Handle, Innsbruck (AT)
- 11.00 – 11.30** **Break**
- 11.30 – 13.00** **Session 7**
Chairs: Carmen Jeronimo, Porto (PT)
 Ellen Zwarthoff, Rotterdam (NL)
- 11.30 – 12.00** **Non-coding RNAs: Concert of new gene expression regulators**
Elena Martens-Uzunova, Rotterdam (NL)
- 12.00 – 12.30** **Dominique Chopin Lecture: Androgen receptor and cytokines - from bench to bedside**
Zoran Culig, Innsbruck (AT)
- 12.30 – 13.00** **Short presentations 5**
- 12.30 – 12.40** **O22 *Integration of functional screening and expression analysis to identify novel microRNAs regulating epithelial-mesenchymal transition in prostate cancer***
Srinivasa Rao, Oxford (GB)
- 12.40 – 12.50** **O23 *Tumor-associated exosomes of urothelial bladder cancer cells affect the tumor microenvironment and support tumorigenesis***
Sophie Baumgart, Homburg (DE)
- 12.50 – 13.00** **O24 *Identification of three long non-coding RNAs that stimulate cell survival in muscle-invasive bladder cancer***
Aleksandra Dudek, Nijmegen (NL)
- 13.00 – 14.00** **Lunch**
- 14.00 – 15.00** **Poster session 2**
Poster numbers P29 to P51 and LBP-1 to LBP-5

15.00 – 16.40	Session 8 Chemoprevention in tumour diseases Chairs: Saverio Bettuzzi, Parma (IT) Hing Leung, Glasgow (GB)
15.00 – 15.30	Metformin and cancer risk and mortality: A systematic review and meta-analysis taking into account biases and confounders Sara Gandini, Milan (IT)
15.30 – 16.00	Chemoprevention Andrea DeCensi, Milan (IT)
16.00 – 16.30	Physiological functions of tea catechins and their practical applications Yukihiko Hara, Tokyo (JP)
16.30 – 16.35	Dominique Chopin Award presented to Zoran Culig Chair: Kerstin Junker, Parma (IT)
16.35 – 16.40	ARTP Award for the best abstract in the field of urological oncology research and closing remarks